IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy

PD-1/PD-L1 is an important signaling pathway in the adaptive immune system. The CD47/SIRPα signaling pathway is a crucial “do not eat me” signal for innate immunity. This study evaluated the anti-tumor mechanism of IMM2520 in vitro and in vivo. IMM2520 was generated using the “mab-trap” platform. IM...

Full description

Saved in:
Bibliographic Details
Main Authors: Chunmei Yang, Song Li, Dianze Chen, Dandan Liu, Yanan Yang, Huiqin Guo, Nana Sun, Xing Bai, Guanghui Li, Ruliang Zhang, Tianxiang Wang, Li Zhang, Liang Peng, Sijin Liu, Wei Zhang, Gui Zhao, Xiaoping Tu, Wenzhi Tian
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Heliyon
Subjects:
PD-L1
CD47
Bispecific antibody
IMM2520
Immune therapy
Antitumor activity
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024158896
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items